Twist Bioscience Corporation Q4 2026 Earnings Call Summary
Twist Bioscience reported positive adjusted EBITDA in Q4 2026, with revenue growth driven by a 175% YoY increase in AI drug discovery. The company expects $550M-$560M revenue in 2027, with $100M from AI drug discovery. It plans $150M in CapEx over two years to support future growth. Management highlighted structural advantages and strategic initiatives in AI and nucleic acid therapeutics.
How this was made

The 30-second read
Why it matters
The earnings call disclosed positive EBITDA, a sizable equity raise, and FY2027 revenue guidance, all of which were not previously public.
Market read
New guidance and capital raise provide fresh material for traders; the stock may react positively in after‑hours trading.
What to watch
Potential dilution from the $425 M equity raise and execution risk of scaling new capacity.
Background
Twist Bioscience is a synthetic DNA manufacturer leveraging a silicon‑based platform for AI‑enabled drug discovery and nucleic‑acid therapeutics.
Ticker impact
Twist Bioscience reported positive adjusted EBITDA and raised $425 million, while guiding FY2027 revenue to $550‑$560 million.
likely upward pressure as investors price in strong guidance and fresh capital.
First disclosure of FY2027 revenue range and sizable equity raise provides new material information.
Market effects
AI‑driven biotech and synthetic DNA platforms may see increased investor interest.
U.S. biotech sector could receive a modest boost.
Limited to biotech investors; no broad market effect.
Counterpoint
Guidance may be overly optimistic given capital intensity and margin headwinds.
Key entities
- companyTwist Bioscience
Synthetic DNA manufacturer (ticker TWST).


